Wolfgang Gesierich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wolfgang Gesierich has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
- Felix J. F. Herth
Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
6 shared publications - Stephan Eisenmann
Department of Respiratory Medicine, Universitätsklinikum Halle , Halle
6 shared publications Frank Reichenberger
40Department for Pneumology, Augustinum, Munich, Germany
5 shared publications- Kaid Darwiche
Department of Pulmonology, Lungenklinik Hemer, Hemer
5 shared publications Andreas Fertl
Department of Internal Medicine and Respiratory Medicine, Krankenhaus Martha-Maria München , Munich
4 shared publicationsBjörn Schwick
Department of Respiratory Medicine, Luisenhospital Aachen
4 shared publications
Latest Publications
- 14 October 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (11-12)
Lung Volume Reduction Surgery in Emphysema With Severely Impaired 6-Minute Walk Distance
- 14 October 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (11-12)
Lung Volume Reduction Surgery in Emphysema With Severely Impaired 6-Minute Walk Distance
- Open Access
- 24 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Progression-survival dissociation in connective tissue disease (CTD)-associated interstitial lung disease (ILD): CTD-ILD versus non-CTD ILD in real-world practice
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a clinically relevant subtype of fibrotic ILD. We compared baseline characteristics, treatment patterns, transplant-free survival (TFS) and progression-free survival (PFS) between CTD-ILD and non-CTD ILD. Methods: In the prospective German INSIGHTS-ILD registry, patients with known CTD status at baseline were classified as CTD-ILD or non-CTD ILD. TFS and PFS were analysed using Kaplan–Meier and log-rank tests. PFS was defined by a prespecified composite end-point including lung function decline, oxygen escalation, 6-min walk distance decline, respiratory hospitalisation, death or clinical worsening prompting any medical therapy escalation or switch. Cox models included the unadjusted Model A; Model B adjusted for age, sex, smoking, comorbidity count and baseline antifibrotic therapy; Model C additionally adjusted for baseline forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide; and Model D additionally adjusted for time since diagnosis. Results: 332 patients (35.7%) had CTD-ILD and 598 (64.3%) had non-CTD ILD. Patients with CTD-ILD were younger, more often female and more frequently received immunomodulatory therapy, whereas antifibrotic use was similar between groups. TFS was similar at 1 year (90.8% versus 90.9%; p=0.57) and at 2 years (83.7% versus 81.9%). In contrast, PFS was higher in CTD-ILD at 1 year (71.8% versus 62.7%; p=0.0032) and 2 years (52.6% versus 41.7%), with less FVC decline over follow-up. CTD-ILD was associated with a lower risk of progression in the unadjusted model (HR 0.73, 95% CI 0.59–0.90; p=0.003) and across all adjusted models. Conclusion: In routine care, CTD-ILD showed similar TFS but better PFS and less FVC decline than non-CTD ILD.
- 24 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessProgression-survival dissociation in connective tissue disease (CTD)-associated interstitial lung disease (ILD): CTD-ILD versus non-CTD ILD in real-world practice
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a clinically relevant subtype of fibrotic ILD. We compared baseline characteristics, treatment patterns, transplant-free survival (TFS) and progression-free survival (PFS) between CTD-ILD and non-CTD ILD. Methods: In the prospective German INSIGHTS-ILD registry, patients with known CTD status at baseline were classified as CTD-ILD or non-CTD ILD. TFS and PFS were analysed using Kaplan–Meier and log-rank tests. PFS was defined by a prespecified composite end-point including lung function decline, oxygen escalation, 6-min walk distance decline, respiratory hospitalisation, death or clinical worsening prompting any medical therapy escalation or switch. Cox models included the unadjusted Model A; Model B adjusted for age, sex, smoking, comorbidity count and baseline antifibrotic therapy; Model C additionally adjusted for baseline forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide; and Model D additionally adjusted for time since diagnosis. Results: 332 patients (35.7%) had CTD-ILD and 598 (64.3%) had non-CTD ILD. Patients with CTD-ILD were younger, more often female and more frequently received immunomodulatory therapy, whereas antifibrotic use was similar between groups. TFS was similar at 1 year (90.8% versus 90.9%; p=0.57) and at 2 years (83.7% versus 81.9%). In contrast, PFS was higher in CTD-ILD at 1 year (71.8% versus 62.7%; p=0.0032) and 2 years (52.6% versus 41.7%), with less FVC decline over follow-up. CTD-ILD was associated with a lower risk of progression in the unadjusted model (HR 0.73, 95% CI 0.59–0.90; p=0.003) and across all adjusted models. Conclusion: In routine care, CTD-ILD showed similar TFS but better PFS and less FVC decline than non-CTD ILD.
- Open Access
- 16 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance
Background: Bronchial rheoplasty (BR) addresses mucosal inflammation and hypersecretion associated with chronic bronchitis (CB) by ablating goblet cell hyperplasia with nonthermal pulsed electric fields. This study assessed if BR continues to demonstrate a safe profile and symptom burden reduction in CB patients. Methods: This observational, post-market, single-arm registry was conducted at eight centres in Austria and Germany. Patients with CB and high symptom burden (COPD assessment test (CAT) score ≥7 points in the first two questions) were treated with two bronchoscopic BR procedures. The primary outcomes were safety and symptom burden at 12 months, evaluated by (serious) adverse events ((S)AEs) and questionnaire scores (CAT and St. George's Respiratory Questionnaire (SGRQ)). Subgroup analyses were performed to identify treatment responders. Results: 106 BR procedures were performed in 54 patients (mean forced expiratory volume in 1 s (FEV 1 ) 57.8±25.3% predicted, residual volume 166.2±39.6% predicted, CAT 24.8±6.8) with a follow-up time of up to 12 months (n=40). The procedure could be performed safely, with only two SAEs (thoracic pain) and 10 respiratory AEs (mainly COPD exacerbation) deemed to be related to the device or procedure over 12 months. Patients experienced statistically significant questionnaire score improvements in CAT (−5.5±8.0 at 6 months, −4.2±7.4 at 12 months) and SGRQ at 6 and 12 months. CAT responders (improvement ≥the minimal clinically important difference of 2 points) had more preserved lung function and better exercise capacity at baseline than CAT nonresponders. Conclusion: The real-world clinical experience demonstrates that BR is a relatively safe and promising treatment option for CB patients with significant symptom burden.
- 16 May 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessBronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance
Background: Bronchial rheoplasty (BR) addresses mucosal inflammation and hypersecretion associated with chronic bronchitis (CB) by ablating goblet cell hyperplasia with nonthermal pulsed electric fields. This study assessed if BR continues to demonstrate a safe profile and symptom burden reduction in CB patients. Methods: This observational, post-market, single-arm registry was conducted at eight centres in Austria and Germany. Patients with CB and high symptom burden (COPD assessment test (CAT) score ≥7 points in the first two questions) were treated with two bronchoscopic BR procedures. The primary outcomes were safety and symptom burden at 12 months, evaluated by (serious) adverse events ((S)AEs) and questionnaire scores (CAT and St. George's Respiratory Questionnaire (SGRQ)). Subgroup analyses were performed to identify treatment responders. Results: 106 BR procedures were performed in 54 patients (mean forced expiratory volume in 1 s (FEV 1 ) 57.8±25.3% predicted, residual volume 166.2±39.6% predicted, CAT 24.8±6.8) with a follow-up time of up to 12 months (n=40). The procedure could be performed safely, with only two SAEs (thoracic pain) and 10 respiratory AEs (mainly COPD exacerbation) deemed to be related to the device or procedure over 12 months. Patients experienced statistically significant questionnaire score improvements in CAT (−5.5±8.0 at 6 months, −4.2±7.4 at 12 months) and SGRQ at 6 and 12 months. CAT responders (improvement ≥the minimal clinically important difference of 2 points) had more preserved lung function and better exercise capacity at baseline than CAT nonresponders. Conclusion: The real-world clinical experience demonstrates that BR is a relatively safe and promising treatment option for CB patients with significant symptom burden.
- Open Access
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
Background: This study aims to report real-life data on the characteristics and treatment patterns of patients with fibrosing interstitial lung disease (ILD; except idiopathic pulmonary fibrosis) across multiple specialised centres in Germany. Eligibility criteria included ILD affecting >10% of lung parenchyma on high-resolution computed tomography, a single breath diffusion capacity for carbon monoxide (DLCO) ≤80% predicted and active treatment of lung disease.Methods: As of the interim analysis cut-off, 655 patients (mean±sdage 65.9±11.7 years, 54.5% male) were included. The most common ILD subtypes were fibrosing hypersensitivity pneumonitis (31.2%), fibrosing ILD (22.0%), rheumatoid arthritis and connective tissue disease ILDs (13.0%) and unclassifiable fibrosing ILD (13.0%).Results: Lung function metrics included total lung capacity at 68.3±17.6% predicted, forced vital capacity at 69.8±19.8% predicted, forced expiratory volume in 1 s at 73.7±19.5% predicted andDLCOat 33.8±15.6% predicted. Current treatments included oral steroids (62.6%), antifibrotic therapy (50.7%), azathioprine (14.4%), methotrexate (10.2%) and mycophenolate mofetil (11.1%). Patients on antifibrotic therapy were typically older at diagnosis and registry inclusion, more often male, had more comorbidities, a lower 6-min walk distance and reduced lung function metrics compared with those not on antifibrotic therapy. Notably, 27.3% of the patients on antifibrotic therapy did not meet progression criteria (INBUILD), whereas 40.1% of patients not receiving antifibrotic therapy did meet those criteria.Conclusion: The patient characteristics observed align with those observed in randomised controlled trials and other noninterventional studies. Patients on antifibrotic therapy generally had more severe disease profiles.
- 27 February 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Open AccessReal-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
Background: This study aims to report real-life data on the characteristics and treatment patterns of patients with fibrosing interstitial lung disease (ILD; except idiopathic pulmonary fibrosis) across multiple specialised centres in Germany. Eligibility criteria included ILD affecting >10% of lung parenchyma on high-resolution computed tomography, a single breath diffusion capacity for carbon monoxide (DLCO) ≤80% predicted and active treatment of lung disease.Methods: As of the interim analysis cut-off, 655 patients (mean±sdage 65.9±11.7 years, 54.5% male) were included. The most common ILD subtypes were fibrosing hypersensitivity pneumonitis (31.2%), fibrosing ILD (22.0%), rheumatoid arthritis and connective tissue disease ILDs (13.0%) and unclassifiable fibrosing ILD (13.0%).Results: Lung function metrics included total lung capacity at 68.3±17.6% predicted, forced vital capacity at 69.8±19.8% predicted, forced expiratory volume in 1 s at 73.7±19.5% predicted andDLCOat 33.8±15.6% predicted. Current treatments included oral steroids (62.6%), antifibrotic therapy (50.7%), azathioprine (14.4%), methotrexate (10.2%) and mycophenolate mofetil (11.1%). Patients on antifibrotic therapy were typically older at diagnosis and registry inclusion, more often male, had more comorbidities, a lower 6-min walk distance and reduced lung function metrics compared with those not on antifibrotic therapy. Notably, 27.3% of the patients on antifibrotic therapy did not meet progression criteria (INBUILD), whereas 40.1% of patients not receiving antifibrotic therapy did meet those criteria.Conclusion: The patient characteristics observed align with those observed in randomised controlled trials and other noninterventional studies. Patients on antifibrotic therapy generally had more severe disease profiles.
- Open Access
- 10 October 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (1)
Clinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline
Background: Data regarding the effectiveness and safety of endoscopic lung volume reduction with valves (ELVR) in emphysema patients with a very low 6-min walk test (6MWT) are limited. Patients with severe emphysema and very low exercise capacity, as indicated by a 6MWT ≤140 m, are often excluded from clinical studies on ELVR, assuming limited therapeutic benefits and increased complication risk.Study designs and methods: This study utilised data from the Lungenemphysemregister e.V., a large German national multi-centre prospective open-label clinical trial, and aimed to assess the outcomes of ELVR in patients with a baseline 6MWT ≤140 m and dyspnoea primarily attributed to hyperinflation.Results: 54 patients with a baseline 6MWT ≤140 m and 365 patients with a baseline 6MWT between 140 and 450 m were included in the study. Baseline characteristics were representative for patients with advanced lung emphysema. Patients with a 6MWT ≤140 m at baseline had a lower forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide and higher symptom burden. In the 3-month follow-up, patients of both groups showed statistically significant improvements in lung function parameters, exercise capacity and quality of life parameters compared to baseline. Patients with a 6MWT ≤140 m at baseline showed significantly more 6MWT improvement compared to patients with baseline 6MWT between 140 and 450 m. Moreover, complication rates were similar in both groups.Interpretation: In summary, the data indicate that ELVR may be an effective and safe treatment for emphysema patients with a very low 6MWT of ≤140 m if very limited exercise capacity is predominately caused by lung emphysema. Therefore future studies should include emphysema patients with a very low 6MWT.
- 10 October 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (1)
Open AccessClinical improvements after endoscopic lung volume reduction with valves in patients with advanced emphysema and a 6-min walk test ≤140 m at baseline
Background: Data regarding the effectiveness and safety of endoscopic lung volume reduction with valves (ELVR) in emphysema patients with a very low 6-min walk test (6MWT) are limited. Patients with severe emphysema and very low exercise capacity, as indicated by a 6MWT ≤140 m, are often excluded from clinical studies on ELVR, assuming limited therapeutic benefits and increased complication risk.Study designs and methods: This study utilised data from the Lungenemphysemregister e.V., a large German national multi-centre prospective open-label clinical trial, and aimed to assess the outcomes of ELVR in patients with a baseline 6MWT ≤140 m and dyspnoea primarily attributed to hyperinflation.Results: 54 patients with a baseline 6MWT ≤140 m and 365 patients with a baseline 6MWT between 140 and 450 m were included in the study. Baseline characteristics were representative for patients with advanced lung emphysema. Patients with a 6MWT ≤140 m at baseline had a lower forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide and higher symptom burden. In the 3-month follow-up, patients of both groups showed statistically significant improvements in lung function parameters, exercise capacity and quality of life parameters compared to baseline. Patients with a 6MWT ≤140 m at baseline showed significantly more 6MWT improvement compared to patients with baseline 6MWT between 140 and 450 m. Moreover, complication rates were similar in both groups.Interpretation: In summary, the data indicate that ELVR may be an effective and safe treatment for emphysema patients with a very low 6MWT of ≤140 m if very limited exercise capacity is predominately caused by lung emphysema. Therefore future studies should include emphysema patients with a very low 6MWT.
- Open Access
- 27 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0292017
Higher in-hospital mortality in SARS-CoV-2 omicron variant infection compared to influenza infection—Insights from the CORONA Germany study
Background: With the emergence of new subvariants, the disease severity of Severe Acute Respiratory Syndrome Coronavirus-2 has attenuated. This study aimed to compare the disease severity in patients hospitalized with omicron variant infection to those with influenza infection. Methods: We compared data from the multicenter observational, prospective, epidemiological “CORONA Germany” (Clinical Outcome and Risk in hospitalized COVID-19 patients) study on patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 to retrospective data on influenza infection cases from November 2016 to August 2022. Severe Acute Respiratory Syndrome Coronavirus-2 cases were classified as wild-type/delta variant before January 2022, or omicron variant from January 2022 onward. The primary outcome was in-hospital mortality, adjusted for age, gender, and comorbidities. Results: The study included 35,806 patients from 53 hospitals in Germany, including 4,916 patients (13.7%) with influenza infection, 16,654 patients (46.5%) with wild-type/delta variant infection, and 14,236 patients (39.8%) with omicron variant infection. In-hospital mortality was highest in patients with wild-type/delta variant infection (16.8%), followed by patients with omicron variant infection (8.4%) and patients with influenza infection (4.7%). In the adjusted analysis, higher age was the strongest predictor for in-hospital mortality (age 80 years vs. age 50 years: OR 4.25, 95% CI 3.10–5.83). Both, patients with wild-type/delta variant infection (OR 3.54, 95% CI 3.02–4.15) and patients with omicron variant infection (OR 1.56, 95% CI 1.32–1.84) had a higher risk for in-hospital mortality than patients with influenza infection. Conclusion: After adjusting for age, gender and comorbidities, patients with wild-type/delta variant infection had the highest risk for in-hospital mortality compared to patients with influenza infection. Even for patients with omicron variant infection, the adjusted risk for in-hospital mortality was higher than for patients with influenza infection. The adjusted risk for in-hospital mortality showed a strong age dependency across all virus types and variants. Trial registration number: NCT04659187.
- 27 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0292017
Open AccessHigher in-hospital mortality in SARS-CoV-2 omicron variant infection compared to influenza infection—Insights from the CORONA Germany study
Background: With the emergence of new subvariants, the disease severity of Severe Acute Respiratory Syndrome Coronavirus-2 has attenuated. This study aimed to compare the disease severity in patients hospitalized with omicron variant infection to those with influenza infection. Methods: We compared data from the multicenter observational, prospective, epidemiological “CORONA Germany” (Clinical Outcome and Risk in hospitalized COVID-19 patients) study on patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 to retrospective data on influenza infection cases from November 2016 to August 2022. Severe Acute Respiratory Syndrome Coronavirus-2 cases were classified as wild-type/delta variant before January 2022, or omicron variant from January 2022 onward. The primary outcome was in-hospital mortality, adjusted for age, gender, and comorbidities. Results: The study included 35,806 patients from 53 hospitals in Germany, including 4,916 patients (13.7%) with influenza infection, 16,654 patients (46.5%) with wild-type/delta variant infection, and 14,236 patients (39.8%) with omicron variant infection. In-hospital mortality was highest in patients with wild-type/delta variant infection (16.8%), followed by patients with omicron variant infection (8.4%) and patients with influenza infection (4.7%). In the adjusted analysis, higher age was the strongest predictor for in-hospital mortality (age 80 years vs. age 50 years: OR 4.25, 95% CI 3.10–5.83). Both, patients with wild-type/delta variant infection (OR 3.54, 95% CI 3.02–4.15) and patients with omicron variant infection (OR 1.56, 95% CI 1.32–1.84) had a higher risk for in-hospital mortality than patients with influenza infection. Conclusion: After adjusting for age, gender and comorbidities, patients with wild-type/delta variant infection had the highest risk for in-hospital mortality compared to patients with influenza infection. Even for patients with omicron variant infection, the adjusted risk for in-hospital mortality was higher than for patients with influenza infection. The adjusted risk for in-hospital mortality showed a strong age dependency across all virus types and variants. Trial registration number: NCT04659187.
- Open Access
- 6 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV1
Introduction: Endoscopic lung volume reduction (ELVR) with one-way valves produces beneficial outcomes in patients with severe emphysema. Evidence on the efficacy remains unclear in patients with a very low forced expiratory volume in 1 s (FEV1) (≤20% predicted). We aim to compare clinical outcomes of ELVR, in relation to the FEV1restriction.Methods: All data originated from the German Lung Emphysema Registry (Lungenemphysem Register), which is a prospective multicentric observational study for patients with severe emphysema after lung volume reduction. Two groups were formed at baseline: FEV1≤20% pred and FEV121–45% pred. Pulmonary function tests (FEV1, residual volume, partial pressure of carbon dioxide), training capacity (6-min walk distance (6MWD)), quality of life (modified Medical Research Council dyspnoea scale (mMRC), COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ)) and adverse events were assessed and compared at baseline and after 3 and 6 months.Results: 33 patients with FEV1≤20% pred and 265 patients with FEV121–45% pred were analysed. After ELVR, an increase in FEV1was observed in both groups (both p121–45% pred group, and by trend in the FEV1≤20% pred group. Pneumothorax was the most frequent complication within the first 90 days in both groups (FEV1≤20% pred: 7.7%versusFEV121–45% pred: 22.1%; p=0.624). No deaths occurred in the FEV1≤20% pred group up to 6 months.Conclusion: Our study highlights the potential efficacy of one-way valves, even in patients with very low FEV1, as these patients experienced significant improvements in FEV1, 6MWD and quality of life. No death was reported, suggesting a good safety profile, even in these high-risk patients.
- 6 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Open AccessAssessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV1
Introduction: Endoscopic lung volume reduction (ELVR) with one-way valves produces beneficial outcomes in patients with severe emphysema. Evidence on the efficacy remains unclear in patients with a very low forced expiratory volume in 1 s (FEV1) (≤20% predicted). We aim to compare clinical outcomes of ELVR, in relation to the FEV1restriction.Methods: All data originated from the German Lung Emphysema Registry (Lungenemphysem Register), which is a prospective multicentric observational study for patients with severe emphysema after lung volume reduction. Two groups were formed at baseline: FEV1≤20% pred and FEV121–45% pred. Pulmonary function tests (FEV1, residual volume, partial pressure of carbon dioxide), training capacity (6-min walk distance (6MWD)), quality of life (modified Medical Research Council dyspnoea scale (mMRC), COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ)) and adverse events were assessed and compared at baseline and after 3 and 6 months.Results: 33 patients with FEV1≤20% pred and 265 patients with FEV121–45% pred were analysed. After ELVR, an increase in FEV1was observed in both groups (both p121–45% pred group, and by trend in the FEV1≤20% pred group. Pneumothorax was the most frequent complication within the first 90 days in both groups (FEV1≤20% pred: 7.7%versusFEV121–45% pred: 22.1%; p=0.624). No deaths occurred in the FEV1≤20% pred group up to 6 months.Conclusion: Our study highlights the potential efficacy of one-way valves, even in patients with very low FEV1, as these patients experienced significant improvements in FEV1, 6MWD and quality of life. No death was reported, suggesting a good safety profile, even in these high-risk patients.
- 27 April 2023
- Published by Springer Nature in Pneumo-News
- Vol. 15 (2) , 6-9
Lungenfibrose als Spätmanifestation einer ANCA-assoziierten Vaskulitis?
- 27 April 2023
- Published by Springer Nature in Pneumo-News
- Vol. 15 (2) , 6-9
Lungenfibrose als Spätmanifestation einer ANCA-assoziierten Vaskulitis?
- Open Access
- 27 December 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (4)
Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD
Targeted lung denervation (TLD) is a novel treatment for COPD with evidence of a potential beneficial effect on exacerbation frequency [1]. It is a minimally invasive procedure involving the ablation of the airway nerve trunks of the vagus nerve that travel parallel to and outside the main bronchi, thereby reducing neuronal acetylcholine release. It has been postulated that TLD may share a similar mechanism of action with the inhaled long-acting muscarinic antagonists [2].
- 27 December 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (4)
Open AccessTargeted lung denervation modulates the mucosal epithelial transcriptome in COPD
Targeted lung denervation (TLD) is a novel treatment for COPD with evidence of a potential beneficial effect on exacerbation frequency [1]. It is a minimally invasive procedure involving the ablation of the airway nerve trunks of the vagus nerve that travel parallel to and outside the main bronchi, thereby reducing neuronal acetylcholine release. It has been postulated that TLD may share a similar mechanism of action with the inhaled long-acting muscarinic antagonists [2].
- 20 October 2022
- Published by Springer Nature in Pneumo-News
- Vol. 14 (5) , 20-21
Nirmatrelvir wirkt auch in der Omikron-Welle
- 20 October 2022
- Published by Springer Nature in Pneumo-News
- Vol. 14 (5) , 20-21
Nirmatrelvir wirkt auch in der Omikron-Welle